Loading...
Market
Will Colossal Biosciences revive the woolly mammoth by end of 2026?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Official announcements from Colossal Biosciences or reputable scientific publications
Story
Colossal Biosciences Raises $200M, Valued at $10.2B to Revive Woolly Mammoth, Dodo, and Tasmanian Tiger
Jan 15, 2025, 09:15 PM
Colossal Biosciences, a Dallas-based startup focused on de-extinction, has raised $200 million in a Series C funding round, bringing its valuation to $10.2 billion. The company, which aims to revive extinct species such as the woolly mammoth, dodo, and Tasmanian tiger, has now secured a total of $435 million in funding since its inception in 2021. The latest round was led by TWG Global, with Mark Walter and Thomas Tull at the helm. Colossal plans to use the new funds to expand its team, develop new technologies, and broaden its list of species targeted for de-extinction.
View original story
Similar markets
Yes • 50%
No • 50%
Tasmanian Tiger • 25%
Other • 25%
Dodo Bird • 25%
Woolly Mammoth • 25%
Other • 25%
Thylacine • 25%
Dodo Bird • 25%
Woolly Mammoth • 25%
Yes • 50%
No • 50%
Germany • 25%
Other • 25%
United States • 25%
China • 25%
WWF • 25%
Conservation International • 25%
The Nature Conservancy • 25%
Other • 25%
